Q-omics provides the consensus-scored PORCN profile across patient tissues and cancer cell-line models. PORCN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PORCN is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PORCN RNA expression shows 18,588 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, COAD, and KIRP as cancer lineages where PORCN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PORCN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PORCN survival associations across molecular data types. PORCN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PORCN RNA expression–survival associations across cancer types. High PORCN expression shows unfavorable associations in MESO, KIRP and LIHC, but favorable associations in UVM, LGG and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PORCN RNA expression.
This table summarizes PORCN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PORCN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PORCN shows lower tumor expression in KIRC and higher tumor expression in COAD, LIHC, UCEC, LUSC and LUAD. The COAD box plot shows higher PORCN RNA expression in tumor versus normal tissue (log2 FC = +1.180, t-test p < 0.001).
This table shows molecular features associated with PORCN in patient tissues and cancer cell lines. In patient samples, PORCN shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PORCN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
